AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

AbbVie bought the rights to SIM0500, a trispecific T-cell engager for multiple myeloma, from Chinese pharmaceutical company Simcere Zaiming for an undisclosed upfront payment and up to $1.05 billion ...

Please provide your email address to receive an email when new articles are posted on . Systemic inflammation mediated 17% of the association between psoriasis severity and subclinical ...

Product Development Science & Technology, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States ...

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

AbbVie's popular arthritis drug Humira saw its patent exclusivity expire in 2023. In the third quarter of 2024, with patients increasingly turning to similar drugs or other prescriptions ...

AbbVie (ABBV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...